Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

421

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

November 30, 2016

Conditions
Osteoarthritis, KneeOsteoarthritis, Hip
Interventions
DRUG

REGN475

DRUG

Placebo

Trial Locations (72)

Unknown

Birmingham

Mobile

Chandler

Phoenix

Tuscon

Hot Spring

Little Rock

Anaheim

Beverly Hills

El Cajon

Sacramento

San Diego

Santa Ana

Thousand Oaks

Upland

Walnut Creek

Lakewood

Clearwater

Fleming Island

Jacksonville

Miami

Orlando

Palm Harbor

Tamarac

Tampa

West Palm Beach

Weston

Winter Haven

Decatur

Honolulu

Chicago

Indianapolis

New Orleans

Elkridge

Frederick

Worcester

Saint Clair Shores

Traverse City

Hattiesburg

Kansas City

St Louis

Omaha

Brooklyn

Hartsdale

New York

Plainview

Rochester

Charlotte

High Point

Raleigh

Cincinnati

Cleveland

Oklahoma City

Tulsa

Bensalem

Duncansville

Jenkintown

Warwick

Mt. Pleasant

Jackson

Jefferson City

Memphis

Cypress

Dallas

Lubbock

Mesquite

Plano

Waco

Salt Lake City

Sandy City

West Jordan

Norfolk

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02447276 - Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip | Biotech Hunter | Biotech Hunter